Regular Inhaled Corticosteroids Use May Protect Against Severe COVID-19 Outcome in COPD

References

• De Vito A, Fiore V, Princic E, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS One. 2021;16(3):e0248009. doi:10.1371/journal.pone.0248009
   PubMed Web of Science ®Google Scholar
• Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi:10.1016/j.rmed.2020.105941
   PubMed Web of Science ®Google Scholar
• Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
   PubMed Web of Science ®Google Scholar
• Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92:1915–1921. doi:10.1002/jmv.25889
   PubMed Web of Science ®Google Scholar
• Calmes D, Graff S, Maes N, et al. Asthma and COPD are not risk factors for ICU stay and death in case of SARS-CoV2 Infection. J Allergy Clin Immunol Pract. 2021;9:160–169 doi:10.1016/j.jaip.2020.09.044
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Rabe A, Loke WJ, et al. Epidemiology, healthcare resource utilization, and mortality of Asthma and COPD in COVID-19: a systematic literature review and meta-analyses. J Asth Aller. 2022;15:811–825. doi:10.2147/JAA.S360985
   PubMed Web of Science ®Google Scholar
• Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J All Clin Immun. 2021;147(2):510–519 doi:10.1016/j.jaci.2020.09.034
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5):2001009. doi:10.1183/13993003.01009-2020
   PubMed Web of Science ®Google Scholar
• Furci F, Caminati M, Senna G, et al. The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19. Clin Mol Allergy. 2021;19:19. doi:10.1186/s12948-021-00159-4
   PubMedGoogle Scholar
• Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. J Virol. 2021;95(1):e01648–20 doi:10.1128/JVI.01648-20
   Google Scholar
• Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106–1120. doi:10.1016/S2213-2600(20)30415-X
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic obstructive lung disease global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease global initiative for chronic obstructive lung disease (2023 report); 2022. Available from: http://www.goldcopd.org/. Accessed November 14, 2022.
   Google Scholar
• Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. The Cochrane database of systematic reviews; 2022:CD015125.
   Google Scholar
• Romagnoli S, Peris A, De Gaudio AR, et al. SARS-CoV-2 and COVID-19: from the Bench to the Bedside. Physiol Rev. 2020;100(4):1455–1466. doi:10.1152/physrev.00020.2020
   PubMed Web of Science ®Google Scholar
• Janssen MT, Ramiro S, Mostard RL, et al. Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study. RMD Open. 2021;7(3):e001906. doi:10.1136/rmdopen-2021-001906
   PubMed Web of Science ®Google Scholar
• Nyberg F, Franzén S, Lindh M, et al. Swedish Covid-19 investigation for future insights – a population epidemiology approach using register linkage (SCIFI-PEARL). CLEP. 2021;13:649–659. doi:10.2147/CLEP.S312742
   Google Scholar
• Zhu Y, Coffman DL, Ghosh D. A boosting algorithm for estimating generalized propensity scores with continuous treatments. J Cau Inf. 2015;3(1):25–40. doi:10.1515/jci-2014-0022
   PubMedGoogle Scholar
• Ridgeway G, McCaffrey D, Morral A, et al. Toolkit for weighting and analysis of nonequivalent groups: a guide to the twang package. Vignette. 2021;2021:26.
   Google Scholar
• Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84–S90.e1. doi:10.1016/j.jclinepi.2013.01.013
   PubMed Web of Science ®Google Scholar
• Funk ML, Westreich D, Wiesen C, et al. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173(7):761–767. doi:10.1093/aje/kwq439
   PubMed Web of Science ®Google Scholar
• Davies JM, Carroll ML, Li H, et al. Budesonide and formoterol reduce early innate anti-viral immune responses in vitro. PLoS One. 2011;6:e27898. doi:10.1371/journal.pone.0027898
   PubMed Web of Science ®Google Scholar
• Simpson JL, Carroll M, Yang IA, et al. Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. Chest. 2016;149:704–713. doi:10.1016/j.chest.2015.12.018
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018;9:2229. doi:10.1038/s41467-018-04574-1
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS Trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi:10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Stone IS, Barnes NC, James WY, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease: a randomized controlled trial. Am. J Respir Crit Care Med. 2016;193:717–726. doi:10.1164/rccm.201508-1647OC
   PubMed Web of Science ®Google Scholar
• Song J-Y, Yoon J-G, Seo Y-B, et al. Ciclesonide inhaler treatment for mild-to-moderate COVID-19: a randomized, open-label, phase 2 trial. J Clin Med. 2021;10(16):3545. doi:10.3390/jcm10163545
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772. doi:10.1016/S2213-2600(21)00160-0
   PubMed Web of Science ®Google Scholar
• Baker JR, Mahdi M, Nicolau DV, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med. 2022;10(6):545–556. doi:10.1016/S2213-2600(22)00002-9
   PubMed Web of Science ®Google Scholar
• Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern Med. 2022;182(1):42–49. doi:10.1001/jamainternmed.2021.6759
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Faner R, Sibila O et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8:436–443. doi:10.1016/S2213-2600(20)30167-3
   PubMed Web of Science ®Google Scholar
• Yu LM, Bafadhel M, Dorward J, et al.; PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 398;2021:843–855. doi:10.1016/S0140-6736(21)01744-X
   PubMed Web of Science ®Google Scholar
• Duvignaud A, Lhomme E, Onaisi R, et al.; Coverage Study Group. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). Clin Microbiol Infect. 2022;28(7):1010–1016. doi:10.1016/j.cmi.2022.02.031
   PubMed Web of Science ®Google Scholar
• Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2- related genes in COPD: results from a randomised controlled trial. Eur Respir J. 2021;58:2100130. doi:10.1183/13993003.00130-2021
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–374. doi:10.1038/s41577-020-0311-8
   PubMed Web of Science ®Google Scholar
• Sen P, Majumdar U, Zein J, et al. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: an analysis of Cleveland Clinic’s COVID-19 registry. PLoS One. 2021;16(6):e0252576. doi:10.1371/journal.pone.0252576
   PubMed Web of Science ®Google Scholar
• Bloom CI, Drake TM, Docherty AB, et al. ISARIC investigators. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9(7):699–711. doi:10.1016/S2213-2600(21)00013-8
   PubMed Web of Science ®Google Scholar
• Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med. 2021;9:909–923 doi:10.1016/S2213-2600(21)00095-3
   PubMed Web of Science ®Google Scholar
• Singh D, Halpin DMG. Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? Lancet Respir Med. 2020;8:1065–1066. doi:10.1016/S2213-2600(20)30447-1
   PubMed Web of Science ®Google Scholar